TYK MEDICINES-B (02410.HK): HK$288.4m share placing
- The 76,000,000 shares comprise 57,000,000 from Anchor International (Qilu) and 19,000,000 from CVG Global, for gross proceeds of about HK$288.8 million.
- The HK$3.80 price is a 7.32% discount to the last trading day's close and a 6.32% premium to the five-day average, for a net price of about HK$3.79.
NewTimeSpace News: On 12 November 2026, after trading hours, TYK Medicines, Inc (stock code: 02410) signed subscription agreements with Anchor International Limited (Qilu) and CVG Global OFC - Pro 1 Fund for 57,000,000 and 19,000,000 new H shares at HK$3.80 each, 76,000,000 shares in total for gross proceeds of about HK$288.8 million. They equal about 20.00% of existing shares and 16.66% of the enlarged base.
The price is a 7.32% discount to the 12 November close of HK$4.100 and a 6.32% premium to the five-day average of HK$3.574, a net HK$3.79 a share. Net proceeds of about HK$288.42 million will go 60% to Phase II and III trials of TY-0540 monotherapy in platinum-resistant ovarian cancer, 30% to Phase II and III trials of TY-0540 with fulvestrant in CDK4/6-resistant breast cancer and 10% to working capital.
- TYK MEDICINES-B (02410.HK): First Kadasa Batch Due 18 November, Shipping by Month-End
- HK Stock Connect Insight | TYK MEDICINES-B (02410.HK): Cut from the Stock Connect list on Sept 7, southbound stake falls from 36.50% to 28.39%
- TYK MEDICINES-B (02410.HK): H Share Subscription Agreement Lapses at Long-stop Date, 63.22 Million Shares
- TYK MEDICINES-B (02410.HK): Chairman Wu Yusheng Buys Additional 635,000 H Shares for HKD 2.09 Million
- TYK MEDICINES-B (02410.HK): Chairman Wu Yusheng Increases Shareholding with Planned Purchases of up to HKD 2 Million, Shares to Be Locked Up for Six Months
